Trial Profile

Phase IIB, Multicenter, Randomized, Open-Label Trial Of CPX-351 (Cytarabine : Daunorubicin) Liposome Injection Versus Intensive Salvage Therapy In Adult Patients ≤ 65 Years Old With AML In First Relapse Following An Initial CR > 1 Month Duration

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 09 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cytarabine/daunorubicin (Primary) ; Anthracyclines; Cytarabine; Daunorubicin; Etoposide; Mitoxantrone
Indications Acute myeloid leukaemia
Focus Therapeutic Use
Sponsors Celator Pharmaceuticals

03 Jun 2013 Multivariate analysis of data from this study and study 204 (profile 700035990) was presented at the American Society of Clinical Oncology 2013 Annual Meeting (ASCO 2013), according to a Celator Pharmaceuticals media release.
05 Jun 2012 Results from a subgroup analysis have been presented at ASCO-2012 according to a Celator media release.
14 Dec 2011 Status changed from active, no longer recruiting to completed.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com